Navigation Links
HistoRx Recognized as a 2010 Company to Watch by the Connecticut Technology Council
Date:10/4/2010

BRANFORD, Conn., Oct. 4 /PRNewswire/ -- HistoRx was recognized as a 2010 Company to Watch by the Connecticut Technology Council at the Innovation Pipeline Awards ceremony last week in New Haven, Connecticut.  HistoRx was recognized for significant milestones achieved in 2010:

  • launching its proprietary AQUA® technology software on a second hardware platform -- the ScanScope FL from Aperio
  • signing a licensing deal with a national oncology reference lab for AQUA technology and several diagnostic assays based on it -- Genoptix Medical Laboratory (Nasdaq: GXDX)
  • receiving a U.S. patent for an application of AQUA technology to personalized medicine -- methods for determining a cancer patient's prognosis based on sub-cellular localization of biomarkers, specifically thymidylate synthase (TS)

These achievements represent key indicators of the company's maturation from a life science technology company to a diagnostics developer nearing first clinical use of its products.

The Innovation & Entrepreneurship Summit is a juried event designed to showcase the products and services from approximately 100 exciting early stage companies in various advanced technology categories.  Each year the event draws several hundred investors, corporate business development executives, prospective customers and the media.  This multifaceted event included a technology showcase of the award-winning Companies to Watch, and focused on young, emerging technology companies with an innovative product or service and the potential to grow quickly.

The Connecticut Technology Council is a statewide association of technology oriented companies and institutions, providing leadership in areas of policy advocacy, community building and assistance for growing companies.  Speaking for over 2,000 companies that employ some 200,000 residents, the Connecticut Technology Council seeks to provide a strong and urgent voice in support of the creation of a culture of innovation.

HistoRx, Inc. is a leading developer of tissue-based theranostic solutions to advance individualized patient care.  The Company's products and services are based on proprietary AQUA® technology for tissue biomarker analysis.  AQUA® software is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decision making.  HistoRx currently helps biopharmaceutical companies advance their product pipelines by generating valuable new insights into the safety and effectiveness of targeted therapeutics in development for cancer and other diseases, and is developing clinical assays based on these insights.  The first clinical diagnostics based on AQUA® technology will be launched in late 2010.  For more information please visit:  www.historx.com.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
2. FreshFx Recognized for use in the Scalder as a Solution to the Yield/Pathogen Reduction Dilemma
3. Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09
4. invivodata Recognized as One of Pittsburghs Fastest Growing Private Companies
5. Roche Scientist Recognized for Excellence in Peptide Chemistry
6. SEI Defined Benefit Client Recognized With Leading Plan Design Award
7. Nonin Medical Recognized for Influential Contributions in Medical Technology
8. China Sky One Medical, Inc.s AMI Diagnostic Kit Recognized as a National Innovation Project by NDRC
9. AQUA(R) Technology Recognized as Promising New Strategy for Hormone Receptor Testing in Breast Cancer by NCCN Task Force
10. Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards
11. Nonin Medical is Recognized by Frost & Sullivan for Remote Patient Monitoring Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... 29, 2016 ReportsnReports.com adds ... market research report that provides an overview of ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:4/29/2016)... 2016 Glycotope GmbH, a clinical-stage ... the appointment of Dr. Alfredo Zurlo as ... oncologist with many years clinical experience and a proven ... last role was at Mologen AG where he was ... Previously Dr. Zurlo held various positions at F Hoffmann ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
Breaking Medicine Technology:
(Date:5/2/2016)... NV (PRWEB) , ... May 02, 2016 , ... ... Pharmacy Times, has announced a new Specialty Pharmacy Patient Satisfaction Award that will ... based on the quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction ...
(Date:5/2/2016)... ... May 02, 2016 , ... The 2016 World Ultimate & Guts Championship (WUGC) Mixed roster was ... made the cut. The WUGC is being held in London, England this year from June ... the men’s division, another gold in the women’s masters division, and a silver in the ...
(Date:5/2/2016)... ... , ... Pregnancy Awareness Month offers a great time to get familiar with ... are ready to have a baby, it’s best to get started before age becomes ... Personal Conception & Pregnancy Organizer, written for women who plan on becoming pregnant to ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... division of Permobil, recently completed two groundbreaking studies that determined that the adjustability ... – are critical in the prevention of pressure injuries, which are now referred ...
(Date:5/2/2016)... Washington, DC (PRWEB) , ... May 02, 2016 , ... ... “ How CMS’s Medicare Part B Payment Model Could Transform the Pharma Landscape .” ... an eye on reducing its spend on provider-administered drugs while preserving care provided to ...
Breaking Medicine News(10 mins):